BIIB News 320.12 09/16/2014 04:30:48 Biogen Idec Inc (BIIB)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 320.12 $BIIB

Biogen/AbbVie Report Positive Data on MS Drug Zinbryta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 4:50PM CDT
Biogen Idec Inc. (BIIB) and partner AbbVie Inc. (ABBV) announced detailed positive results from the phase III study on Zinbryta.

SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 1.01% Loss
Comtex SmarTrend(R) - Mon Sep 15, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $315.71 to a high of $323.97. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $321.11 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Amarin Plunges after the FDA Denies Vascepa SPA Appeal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 3:45PM CDT
Amarin Corporation (AMRN) announced that the FDA's Office of New Drugs denied the company's appeal regarding the rescission of the Special Protocol Assessment covering the phase III ANCHOR study on Vascepa.

Nasdaq Falls Hard, But Apple Resilient On iPhone Orders
at Investor's Business Daily - Mon Sep 15, 1:55PM CDT
The Dow Jones industrial average and S&P 500 traded in a tight range Monday, but the Nasdaq took a beating as profit-taking hit several recent highfliers. The Nasdaq moved off lows but still fell 0.9%, hurt by weakness in Tesla Motors (TSLA). Shares...

Event Schedules, Survey Findings, Regulatory Filings, and Market Activity - Research Reports on Amgen, Biogen Idec, Salix, Covidien and Shire
PR Newswire - Mon Sep 15, 7:50AM CDT
Today, Analysts Review released its research reports regarding Amgen Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Covidien plc (NYSE: COV) and Shire plc (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6458-100free.

Health Care Sector Stocks Technical Review - Ampio Pharma, InterMune, Biogen Idec, Hologic, and CareFusion Corp.
PR Newswire - Mon Sep 15, 7:40AM CDT
On Friday, September 12, 2014, the NASDAQ Composite ended at 4,567.60, down 0.53%, the Dow Jones Industrial Average finished the day 0.36% lower at 16,987.51, and the S&P 500 closed at 1,985.54, down 0.60%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 736.69, down 0.69%, while the index has advanced 2.86% in the last one month. Investor-Edge has initiated coverage on the following equities: Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE), InterMune Inc. (NASDAQ: ITMN), Biogen Idec Inc. (NASDAQ: BIIB), Hologic Inc. (NASDAQ: HOLX), and CareFusion Corporation (NYSE: CFN). Free research on these five companies can be accessed at:

Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers
at Investor's Business Daily - Sat Sep 13, 7:02AM CDT
Biotech and pharmaceutical companies are on the rise with life-saving promises, adding to hopes that their stocks will also be healthy investments. The industry was down Friday on general market weakness and concerns over growth stocks. But it...

Sanofi Reports Data on Multiple Sclerosis Drug Lemtrada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 4:30PM CDT
Sanofi's (SNY) subsidiary, Genzyme, announced positive interim data on its multiple sclerosis (MS) candidate, Lemtrada (alemtuzumab), from the second year of an extension study.

Biogen Reports Positive Two-Year Data on MS Drug Plegridy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 3:30PM CDT
Biogen Idec Inc. (BIIB) announced encouraging data from the phase III ADVANCE study on Plegridy in patients suffering from relapsing+remitting multiple sclerosis.

Critical Alerts For U.S. Bancorp, Nuverra Environmental Solutions, Biogen, Deere and Philip Morris International Released By InvestorsObserver
PR Newswire - Fri Sep 12, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for USB, NES, BIIB, DE and PM.

Why Biogen Idec Inc's Stock is Up 17% in 2014
Todd Campbell, The Motley Fool - Motley Fool - Fri Sep 12, 7:43AM CDT
Source: Biogen Idec Biogen Idec's stock has returned about 17% this year. That's good enough to outpace the S&P 500 index's 8.9% return, but not quite as good as the Nasdaq Biotechnology index's 19% return. Since Biogen is one of...

Detailed Results from Biogen Idec and AbbVie's Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA(TM) (Daclizumab High-Yield Process)
Business Wire - Fri Sep 12, 6:30AM CDT
--a^' First Presentation of Full DECIDE Results at ACTRIMS-ECTRIMS Meeting -

Novartis Presents Data on Multiple Sclerosis Drug Gilenya - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 4:55PM CDT
Novartis (NVS) has presented encouraging data on MS drug, Gilenya, from a follow-up extension study, LONGTERMS, at the Joint ACTRIMS-ECTRIMS Meeting in Boston.

After Yesterday's Decline of 1.50%, Biogen Idec Offers Investors Better Value
Comtex SmarTrend(R) - Thu Sep 11, 3:46PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $324.74 to a high of $332.81. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $325.99 on volume of 921,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Stocks Show Modest Losses; Biotechs Pressured Again
at Investor's Business Daily - Thu Sep 11, 1:46PM CDT
Major averages showed modest losses with a little over one hour remaining in Thursday's session. The Nasdaq lost 0.2%, hurt somewhat by a fresh round of selling in biotechland. The Dow Jones industrial average and S&P 500 gave up 0.2% and 0.1%,...

Trading Guidelines for Amgen, Biogen Idec, Gilead, 3 Other Biotechs
at The Street - Thu Sep 11, 9:02AM CDT
Here are some numbers that may help you navigate the volatile and expensive biotech sector.

New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA(R) (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients
Business Wire - Thu Sep 11, 6:30AM CDT
--- Positive Clinical and MRI Outcomes in Newly Diagnosed Patients -

PLEGRIDY(TM) (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in Multiple Sclerosis Patients
Business Wire - Thu Sep 11, 6:30AM CDT
Today Biogen Idec (NASDAQ: BIIB) announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY(TM) (peginterferon beta-1a) were maintained in people with relapsing forms of multiple sclerosis (RMS) beyond the first year of the study. These results were presented at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS) in Boston.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 137

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
Condo Downsizing Demands More Than a Price Check Today

Updated Category News Views 58

A smaller front door can hide a surprisingly large stack of obligations. That is the useful point in the HelloNation guidance featuring Chevy Chase real estate expert Lise Howe: downsizing into a condo is not merely a square-footage trade. It is a decision about recurring costs, building stewardship, daily friction, and whether the place still works when life gets less...

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 58

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
Leqembi’s Real-World Data Gives BioArctic More Weight

Updated Category News Views 133

A Harder Look at Treatment Staying Power Alzheimer’s drug data rarely arrive without a thicket of caveats, and that is exactly why this Leqembi update deserves a calm read rather than a victory lap. BioArctic’s partner Eisai presented a three-year real-world analysis at CTAD 2026 covering 560 early Alzheimer’s patients across 13 U.S. sites. The headline is striking:...

Continue Reading
Yoodli's No. 9 Ranking Signals Enterprise AI Traction

Updated Category News Views 58

Ninth place can be easy to dismiss until you notice the company is sitting near the top of a 500-name growth list. Yoodli's No. 9 position on Deloitte's 2026 Technology Fast 500 is a meaningful signal that its AI-based coaching and workforce-skills pitch is getting traction inside large organizations. It is not a revenue disclosure, it is not a valuation marker, and...

Continue Reading
MetaOptics Tests a Real Path Into Secure Imaging Markets

Updated Category News Views 68

Fingerprint scanners have never impressed me much; fooling one is exactly the sort of nuisance that keeps security buyers spending. MetaOptics’ new collaboration with Hong Kong’s ASTRI goes after that uncomfortable problem with a compact nano-optics imaging system built for biometric security and smart sensing. It is a sensible target. It is also, at this stage, a...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 159

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 254

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Mar-Jac's Safety Milestone Carries Real Operational Weight

Updated Category News Views 62

Four million worked hours without a lost-time accident is the sort of number that ought to make people pause, especially in poultry processing. Mar-Jac Poultry’s Gainesville facility earned Workplace Safety recognition from the Greater Hall Chamber of Commerce after reaching that mark, and this is one corporate achievement that deserves a little less eye-rolling than...

Continue Reading
Tim Hortons Bets on ELF Cheer for U.S. Holiday Visits

Updated Category News Views 35

Nothing says holiday restaurant marketing quite like putting spaghetti-shaped whipped topping on hot chocolate and trusting a 2003 movie to do the selling. Tim Hortons is rolling out an ELF-inspired menu at participating U.S. locations starting November 18, 2026, pairing the chain with Warner Bros. Consumer Products and mining Buddy the Elf's sugar-fueled world for a...

Continue Reading

Top 5 Most Recently Viewed Articles

T&T Supermarkets Expands Presence with New Store Opening

Updated Category News Views 466

T&T Supermarkets Unveils Plans for a Major New Store T&T Supermarket Inc., Canada's largest Asian grocery retailer, is excited to share plans for their newest store in California, which will be located at Crossroads Marketplace in Chino Hills. This store will span an impressive 61,000 square feet, providing ample space for a wide variety of products and services to meet...

Continue Reading
Autohome Inc. Unveils its Comprehensive 2024 ESG Report

Updated Category News Views 268

Autohome Inc. Releases 2024 ESG Report Autohome Inc. (NYSE: ATHM) has shared its 2024 Environmental, Social, and Governance (ESG) report. This document emphasizes the firm's commitment to sustainable practices and highlights their ongoing journey towards eco-friendly solutions within the automobile sector. Insights from the ESG Report The report details the extensive ESG...

Continue Reading
Nintendo and The Pokemon Company Pursue Legal Action Against Palworld

Updated Category News Views 87

Nintendo and The Pokemon Company Take Legal Action Nintendo and The Pokemon Company have officially initiated a patent infringement lawsuit against the creators of the popular survival adventure game, "Palworld." This development has caught the attention of both gamers and industry experts alike. Details of the Lawsuit Reports indicate that the lawsuit was filed on...

Continue Reading
NYCM Insurance Achieves Elite Winner Status for Wellness

Updated Category News Views 118

NYCM Insurance Celebrated for Wellness Excellence NYCM Insurance proudly announces its recognition as an "Elite Winner" among the Nation's Best and Brightest in Wellness. This marks an outstanding milestone for the company, achieving the accolade for the twelfth consecutive year, a testament to their dedication to enhancing employee wellness. Commitment to Employee...

Continue Reading
Antonio Filosa Leads Stellantis with Newly Formed Team

Updated Category News Views 284

New Leadership Structure at Stellantis Under Antonio Filosa Today marks a significant milestone for Stellantis N.V. as Antonio Filosa steps into the role of Chief Executive Officer. Alongside this transition, he has unveiled an exciting new leadership team, showcasing a strong lineup of industry veterans and decision-makers from across Stellantis’ diverse operations...

Continue Reading